Triple Negative Breast Cancer (TNBC)
Conditions
Keywords
Phase Ib, TNBC, advanced, metastatic, immunotherapy, PDR001,, LAG525, NIR178, INC280, MCS110, ACZ885
Brief summary
This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses of spartalizumab + LAG525 in combination with partner investigational drugs to be escalated until the MTD is reached or a lower RDE is established: NIR178, capmatinib, MCS110, or canakinumab. It is anticipated that other partner study drugs may be added in the future by protocol amendment. After the determination of the MTD/RDE for a particular treatment arm, dose expansion may begin in that arm in order to further assess safety, tolerability, PK/PD, and anti-tumor activity of each combination at the MTD/RDE. Dose expansion arms may initiate only after consideration by the Investigators and Novartis of all available toxicity information, the assessment of risk to future patients from the BLRM, and the available PK, preliminary efficacy, and PD information. There is no requirement for dose-escalation treatment arms reaching an MTD/RDE to proceed to dose expansion.
Interventions
BIOLOGICALspartalizumab
LIVI (Liquid in vial) Concentrate for Solution for infusion
BIOLOGICALLAG525
LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
DRUGNIR178
Capsule
DRUGcapmatinib
Tablet
BIOLOGICALMCS110
LIVI (Liquid in vial) Concentrate for Solution for infusion
BIOLOGICALcanakinumab
LIVI (Liquid in vial) Solution for injection
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Patients with advanced/metastatic TNBC (defined as HER-2 negative with \<1% of tumor cell nuclei immunoreactive for estrogen receptor (ER) and progesterone receptor (PR)), with measurable disease as determined by RECIST version 1.1 (refer to Appendix 16.1). Tumor lesions previously irradiated or subjected to other loco-regional therapy will only be considered measurable if there is documented disease progression at the treated site prior to study entry. * Patients should have received standard chemotherapy for advanced or metastatic disease but should not have received more than 2 prior lines of chemotherapy. Neoadjuvant or adjuvant chemotherapy will count as one prior line. * Patients must have received prior systemic treatment that included taxane-based chemotherapy for neoadjuvant or metastatic disease. * Patients must have a site of disease amenable to core needle biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at screening, and during therapy on the study. Exceptions may be considered after documented discussion with Novartis. Patients with available archival tumor tissue obtained ≤6 months prior to study treatment initiation do not need to undergo a new tumor biopsy at screening, if the patient has not received any anti-cancer therapy since the biopsy was taken, and if adequate tissue is available. Main
Exclusion criteria
applicable to all treatment arms: * Patient has received prior treatment with anti-LAG-3, anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody (any line of therapy). * Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 2 weeks prior to initiating study treatment. * History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients. * Impaired cardiac function or clinically significant cardiac disease. * HIV infection. * Patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, including those with inactive disease for patients receiving either capmatinib, MCS110 or canakinumab. * Active, known or suspected autoimmune disease. * History of or current interstitial lung disease or pneumonitis grade ≥ 2. * Subjects with tuberculosis (TB), for patients receiving either MCS110 or canakinumab. Other eligibility criteria apply.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | at month 18 | Month 18 is assumed to be study end |
| Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | at month 18 | Month 18 is assumed to be study end |
| Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only) | at Day 28 | end of first cycle |
| Frequency of dose interuptions | at month 18 | Month 18 is assumed to be study end |
| Frequency of dose reductions | at month 18 | Month 18 is assumed to be study end |
| Dose intensities | at month 18 | Month 18 is assumed to be study end |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum concentration of spartalizumab, LAG525, MCS110, canakinumab | at Day 1, Day 8, Day 15, Day 29, Day 57, Day 65, Day 70, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
| Plasma concentration of NIR178, NJI675, capmatinib | at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
| PK parameter (Tmax) of spartalizumab | at month 12 | cycle 12 |
| PK parameter (Cmax) of spartalizumab | at month 12 | cycle 12 |
| PK parameter (AUC) of spartalizumab | at month 12 | cycle 12 |
| PK parameter (Tmax) of LAG525 | at month 12 | cycle 12 |
| PK parameter (Cmax) of LAG525 | at month 12 | cycle 12 |
| PK parameter (AUC) of LAG525 | at month 12 | cycle 12 |
| PK parameter (Tmax) of NIR178 | at month 12 | cycle 12 |
| PK parameter (Cmax) of NIR178 | at month 12 | cycle 12 |
| Best overall response (BOR) | at month 18 | Month 18 is assumed to be study end |
| PK parameter (Tmax) of capmatinib | at month 12 | cycle 12 |
| PK parameter (Cmax) of capmatinib | at month 12 | cycle 12 |
| PK parameter (AUC) of capmatinib | at month 12 | cycle 12 |
| PK parameter (Tmax) of MCS110 | at month 12 | cycle 12 |
| PK parameter (Cmax) of MCS110 | at month 12 | cycle 12 |
| PK parameter (AUC) of MCS110 | at month 12 | cycle 12 |
| PK parameter (Tmax) of canakinumab | at month 12 | cycle 12 |
| PK parameter (Cmax) of canakinumab | at month 12 | cycle 12 |
| PK parameter (AUC) of canakinumab | at month 12 | cycle 12 |
| Changes from baseline of PD markers in tumor tissue (TILs, CD8, PD-L1, LAG-3) | at baseline and at Day 43 | — |
| PK parameter (AUC) of NIR178 | at month 12 | cycle 12 |
| Progression free survival (PFS) per RECIST v1.1 and iRECIST | at month 18 | Month 18 is assumed to be study end |
| Presence of anti-spartalizumab antibodies | at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
| Presence of anti-LAG525 antibodies | at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
| Presence of anti-MCS110 antibodies | at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
| Presence of anti-canakinumab antibodies | at Day 1, Day 29, Day 57, Day 85, Day 113, Day 141, Day 197, Day 253, Day 309 and EOT | — |
Countries
Australia, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore, Spain, United States
Outcome results
None listed